These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33483290)

  • 1. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese.
    Guaraná M; Soares A; Daumas A; Biasoli I; Solza C
    Hematol Transfus Cell Ther; 2022; 44(3):321-327. PubMed ID: 33483290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
    Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
    J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.
    Găman MA; Scherber RM; Ursuleac I; Crişan AM; Bădeliţă SN; Ionescu BO; Ghiaur AE; Brînză M; Pîrciulescu N; Lascăr TO; Diaconu CC; Găman AM; Coriu D
    J Clin Med; 2024 Jun; 13(11):. PubMed ID: 38892995
    [No Abstract]   [Full Text] [Related]  

  • 4. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
    Langlais BT; Mazza GL; Kosiorek HE; Palmer J; Mesa R; Dueck AC
    J Hematol; 2021 Oct; 10(5):207-211. PubMed ID: 34804309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms with Relation to Genetic Burden and Thrombosis.
    Ümit EG; Baysal M; Kırkızlar HO; Demir AM
    Turk J Haematol; 2024 Aug; 41(3):175-181. PubMed ID: 38801033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
    Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
    Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Burden of symptoms and Quality of life of Filipino patients with Myeloproliferative neoplasm: A Multicenter Cross-sectional survey.
    Mesina FZ; Dumagay TE; Alejandria MM
    Asia Pac J Clin Oncol; 2024 Jul; ():. PubMed ID: 39021300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
    Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
    Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
    Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
    Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
    BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS.
    Shumeiko OO; Poluben LO; Klimuk BT; Rybchenko LA; Neumerzhitskaya LV; Verbilenko RM; Frolov SV; Klymenko SV
    Probl Radiac Med Radiobiol; 2018 Dec; 23():510-516. PubMed ID: 30582868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The personal impact of living with a myeloproliferative neoplasm.
    Eppingbroek AAM; Lechner L; Bakker EC; Nijkamp MD; de Witte MA; Bolman CAW
    Psychooncology; 2024 Apr; 33(4):e6338. PubMed ID: 38610117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
    Mesa R; Boccia RV; Grunwald MR; Oh ST; Colucci P; Paranagama D; Parasuraman S; Stein BL
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):590-596. PubMed ID: 30122202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
    Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
    Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
    Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
    [No Abstract]   [Full Text] [Related]  

  • 16. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
    Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
    Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
    Le Gall-Ianotto C; Ficheux AS; Lippert E; Herbreteau L; Rio L; Pan-Petesch B; Misery L; Ianotto JC
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1175-1183. PubMed ID: 36808754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to MPN Symptom Assessment.
    Geyer H; Mesa RA
    Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.
    Anderson LA; James G; Duncombe AS; Mesa R; Scherber R; Dueck AC; de Vocht F; Clarke M; McMullin MF
    Am J Hematol; 2015 Oct; 90(10):864-70. PubMed ID: 26113113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.